| Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ... New England Journal of Medicine 376 (2), 125-135, 2017 | 3145 | 2017 |
| Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ... The Lancet 395 (10236), 1547-1557, 2020 | 781 | 2020 |
| Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome MH Kulke, D Hörsch, ME Caplin, LB Anthony, E Bergsland, K Öberg, ... Journal of clinical oncology 35 (1), 14-23, 2017 | 365 | 2017 |
| 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long … JR Strosberg, ME Caplin, PL Kunz, PB Ruszniewski, L Bodei, A Hendifar, ... The Lancet Oncology 22 (12), 1752-1763, 2021 | 364 | 2021 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 281 | 2017 |
| The dual kinase complex FAK-Src as a promising therapeutic target in cancer V Bolós, JM Gasent, S López-Tarruella, E Grande OncoTargets and therapy, 83-97, 2010 | 247 | 2010 |
| Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study J Strosberg, N Mizuno, T Doi, E Grande, JP Delord, R Shapira-Frommer, ... Clinical cancer research 26 (9), 2124-2130, 2020 | 202 | 2020 |
| Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis M Santoni, A Rizzo, J Kucharz, V Mollica, M Rosellini, A Marchetti, ... Cancer Immunology, Immunotherapy 72 (6), 1365-1379, 2023 | 140 | 2023 |
| Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy O Martínez-Sáez, PG Borau, T Alonso-Gordoa, J Molina-Cerrillo, ... Critical reviews in oncology/hematology 111, 117-123, 2017 | 128 | 2017 |
| A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)+ tremelimumab (T)+ enfortumab vedotin (EV) or D+ EV for neoadjuvant … T Powles, A Drakaki, JYC Teoh, E Grande, M Fontes-Sousa, C Porta, ... Journal of Clinical Oncology 40 (6_suppl), TPS579-TPS579, 2022 | 22 | 2022 |
